Worldwide Blockbusters’ Movements (Alliance and Collaboration within this December)
On Dec. 20, 2012, CEVEC Pharmaceuticals (“CEVEC”), the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation (“Yuhan”) based in Seoul, South Korea announced the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.
On Dec. 20, 2012, Nikon Corporation (Makoto Kimura, President) and A*STAR Institute of Microelectronics (IME), a leading semiconductor research institute of Singapore, have announced a collaboration with an agreement to jointly set up a research and development (R&D) laboratory to develop advanced optical lithography technology used in the manufacturing of semiconductor chips .
On Dec. 20, 2012, Humedica, Inc., a clinical intelligence company, and Pfizer Inc. (NYSE: PFE), the world’s largest research-based biopharmaceutical company, announced a multi-year strategic alliance to jointly advance capabilities to derive insights from real world data to improve patient outcomes and overall health.
On Dec. 20, 2012, AIMM Therapeutics, a therapeutic antibody company, announced a strategic partnership with Cosmo Pharmaceuticals (SIX: COPN), Milan, Italy, to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma. Under the agreement, Cosmo Pharmaceuticals will formulate novel human monoclonal antibodies generated by AIMM Therapeutics in an extended release form exploiting its proprietary MMX® technology.
On Dec. 19, 2012, AstraZeneca will collaborate with Fudan University to discover the mechanism behind leonurine, a TCM product derived from Herba Leonuri that is used to treat heart disease, ischemic stroke and atherosclerosis. AstraZeneca will underwrite the cost of two years of research with the hope of discovering a new treatment for cardiovascular diseases.